{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:55:23Z","timestamp":1773460523201,"version":"3.50.1"},"reference-count":128,"publisher":"Scientific Scholar","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol Venereol Leprol"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/0378-6323.184199","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T09:40:04Z","timestamp":1466070004000},"page":"626","source":"Crossref","is-referenced-by-count":6,"title":["Anticoagulants in dermatology"],"prefix":"10.25259","volume":"82","author":[{"given":"ArunC","family":"Inamadar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KeshavmurthyA","family":"Adya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparna","family":"Palit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0378-6323.184199-1","first-page":"83","volume-title":"Anticoagulants: A review of the pharmacology, dosing, and complications","author":"Alquwaizani","year":"2013","journal-title":"Curr Emerg Hosp Med Rep"},{"key":"key-10.4103\/0378-6323.184199-2","first-page":"961","volume-title":"Livedoid vasculopathy: An intringuing cutaneous disease","author":"Criado","year":"2011","journal-title":"An Bras Dermatol"},{"key":"key-10.4103\/0378-6323.184199-3","first-page":"52","volume-title":"New oral anticoagulants: Should they replace heparins and warfarin?","author":"Tsiara","year":"2011","journal-title":"Hellenic J Cardiol"},{"key":"key-10.4103\/0378-6323.184199-4","first-page":"3","volume-title":"Reticulate dermatoses","author":"Adya","year":"2014","journal-title":"Indian J Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0019-5154","issn-type":"print"},{"key":"key-10.4103\/0378-6323.184199-5","first-page":"1340","volume-title":"Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs \u2013 A prospective study","author":"Di","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0378-6323.184199-6","first-page":"1466","volume-title":"Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G\/4G) treated successfully with tissue plasminogen activator","author":"Deng","year":"2006","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0378-6323.184199-7","first-page":"259","volume-title":"Therapeutic use of low molecular weight heparin for capillaritis alba","author":"Hesse","year":"2008","journal-title":"Phlebologie"},{"key":"key-10.4103\/0378-6323.184199-8","first-page":"431","volume-title":"Livedoid vasculopathy and hypercoagulability in a patient with primary Sj\u00f6gren's syndrome","author":"Cardoso","year":"2007","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/0378-6323.184199-9","first-page":"98","volume-title":"Case of livedoid vasculopathy with peripheral neuropathy successfully treated with low-dose warfarin","author":"Osada","year":"2010","journal-title":"J Dermatol"},{"key":"key-10.4103\/0378-6323.184199-10","first-page":"512","volume-title":"Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarin","author":"Davis","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.184199-11","first-page":"121","volume-title":"A case of livedoid vasculopathy associated with factor V Leiden mutation: Successful treatment with oral warfarin","author":"Kavala","year":"2008","journal-title":"J Dermatolog Treat"},{"key":"key-10.4103\/0378-6323.184199-12","doi-asserted-by":"crossref","unstructured":"Hairston BR, Davis MD, Gibson LE, Drage LA. Treatment of livedoid vasculopathy with low-molecular-weight heparin: Report of 2 cases. Arch Dermatol 2003;139:987-90.","DOI":"10.1001\/archderm.139.8.987"},{"key":"key-10.4103\/0378-6323.184199-13","first-page":"1011","volume-title":"Difficult management of livedoid vasculopathy","author":"Franc\u00e8s","year":"2004","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0378-6323.184199-14","first-page":"237","volume-title":"Atrophie blanche: A clinicopathological study of 27 patients","author":"Yang","year":"1991","journal-title":"Chang Gung Med J"},{"key":"key-10.4103\/0378-6323.184199-15","first-page":"e73","volume-title":"A phase II multicenter trial with rivaroxaban in the treatment of livedoid vasculopathy assessing pain on a visual analog scale","author":"Drabik","year":"2014","journal-title":"JMIR Res Protoc"},{"key":"key-10.4103\/0378-6323.184199-16","doi-asserted-by":"crossref","unstructured":"Levin M, Eley B, Faust SN. Purpura fulminans. In: Irvine A, Hoeger P, Yan A, editors. Harper's Textbook of Pediatric Dermatology. 3rd ed. Oxford: Wiley-Blackwell; 2011. p. 162.1-162.16.","DOI":"10.1002\/9781444345384.ch162"},{"key":"key-10.4103\/0378-6323.184199-17","first-page":"201","volume-title":"Empiric treatment of protracted idiopathic purpura fulminans in an infant: A case report and review of the literature","author":"Macheret","year":"2011","journal-title":"J Med Case Rep"},{"key":"key-10.4103\/0378-6323.184199-18","first-page":"1066","volume-title":"Purpura fulminans: Recognition, diagnosis and management","author":"Chalmers","year":"2011","journal-title":"Arch Dis Child"},{"key":"key-10.4103\/0378-6323.184199-19","first-page":"318","volume-title":"Diagnosis and management of neonatal purpura fulminans","author":"Price","year":"2011","journal-title":"Semin Fetal Neonatal Med"},{"key":"key-10.4103\/0378-6323.184199-20","first-page":"867","volume-title":"The role of heparin in the prevention of extremity and digit necrosis in meningococcal purpura fulminans","author":"Kuppermann","year":"1994","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.4103\/0378-6323.184199-21","first-page":"581","volume-title":"Review of management of purpura fulminans and two case reports","author":"Nolan","year":"2001","journal-title":"Br J Anaesth"},{"key":"key-10.4103\/0378-6323.184199-22","first-page":"598","volume-title":"Novel management of post varicella purpura fulminans owing to severe acquired protein S deficiency","author":"Thomson","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"key":"key-10.4103\/0378-6323.184199-23","first-page":"1214","volume-title":"Protein C deficiency","author":"Goldenberg","year":"2008","journal-title":"Haemophilia"},{"key":"key-10.4103\/0378-6323.184199-24","first-page":"e1435","volume-title":"Anticoagulant treatment with rivaroxaban in severe protein S deficiency","author":"Martinelli","year":"2013","journal-title":"Pediatrics"},{"key":"key-10.4103\/0378-6323.184199-25","first-page":"756","volume-title":"Homozygous protein C deficiency: Description of a new mutation and successful treatment with low molecular weight heparin","author":"Monagle","year":"1998","journal-title":"Thromb Haemost"},{"key":"key-10.4103\/0378-6323.184199-26","first-page":"127","volume-title":"Current management of superficial thrombophlebitis of the lower limb","author":"Giannoukas","year":"2013","journal-title":"Phlebolymphology"},{"key":"key-10.4103\/0378-6323.184199-27","first-page":"131","volume-title":"Superficial thrombophlebitis: Epidemiology, physiopathology, diagnosis and treatment","author":"SobreiraI","year":"2008","journal-title":"J Vasc Bras"},{"key":"key-10.4103\/0378-6323.184199-28","first-page":"160","volume-title":"Therapeutic management of superficial venous thrombosis with calcium nadroparin.Dosage testing and comparison with a non-steroidal anti-inflammatory agent","author":"Titon","year":"1994","journal-title":"Ann Cardiol Angeiol (Paris)"},{"key":"key-10.4103\/0378-6323.184199-29","first-page":"1657","volume-title":"A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis","author":"Superficial","year":"2003","journal-title":"Arch Intern Med"},{"key":"key-10.4103\/0378-6323.184199-30","first-page":"833","volume-title":"A randomized trial of dalteparin compared with ibuprofen for the treatment of superficial thrombophlebitis","author":"Rathbun","year":"2012","journal-title":"J Thromb Haemost"},{"key":"key-10.4103\/0378-6323.184199-31","first-page":"523","volume-title":"High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg.A prospective, controlled, randomized study","author":"Marchiori","year":"2002","journal-title":"Haematologica"},{"key":"key-10.4103\/0378-6323.184199-32","first-page":"616","volume-title":"Preliminary results of a nonoperative approach to saphenofemoral junction thrombophlebitis","author":"Ascer","year":"1995","journal-title":"J Vasc Surg"},{"key":"key-10.4103\/0378-6323.184199-33","first-page":"1152","volume-title":"High vs.low doses of low-molecular-weight heparin for the treatment of superficial vein thrombosis of the legs: A double-blind, randomized trial","author":"Prandoni","year":"2005","journal-title":"J Thromb Haemost"},{"key":"key-10.4103\/0378-6323.184199-34","first-page":"9","volume-title":"Liposomal heparin spray: A new formula in adjunctive treatment of superficial venous thrombosis","author":"G\u00f3rski","year":"2005","journal-title":"Angiology"},{"key":"key-10.4103\/0378-6323.184199-35","first-page":"375","volume-title":"Liposomal heparin-spraygel in comparison with subcutaneous low molecular weight heparin in patients with superficial venous thrombosis.A randomized, controlled, open multicentre study","author":"Katzenschlager","year":"2003","journal-title":"J Kardiol"},{"key":"key-10.4103\/0378-6323.184199-36","first-page":"CD004982","volume-title":"Treatment for superficial thrombophlebitis of the leg","author":"Di","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/0378-6323.184199-37","first-page":"CD004982","volume-title":"Treatment for superficial thrombophlebitis of the leg","author":"Di","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/0378-6323.184199-38","first-page":"1222","volume-title":"Fondaparinux for the treatment of superficial-vein thrombosis in the legs","author":"Decousus","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.184199-39","first-page":"e419S","volume-title":"Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"key-10.4103\/0378-6323.184199-40","unstructured":"Rosh AJ, Khait L, Rowe VL. Superficial Thrombophlebitis Treatment & Management. Available from: http:\/\/www.emedicine.medscape.com\/article\/463256-treatment#d11. [Last accessed on 2015 Jun 24]."},{"key":"key-10.4103\/0378-6323.184199-41","first-page":"28","volume-title":"Prophylactic dose fondaparinux for 6 weeks in superficial thrombophlebitis of the legs reduces the risk for symptomatic thromboembolic complications","author":"DeSancho","year":"2013","journal-title":"Evid Based Med"},{"key":"key-10.4103\/0378-6323.184199-42","first-page":"523","volume-title":"Superficial thrombophlebitis of the legs: A randomized, controlled, follow-up study","author":"Belcaro","year":"1999","journal-title":"Angiology"},{"key":"key-10.4103\/0378-6323.184199-43","unstructured":"Patel K, Chun LJ, Brenner BE. Deep Venous Thrombosis. Available from: http:\/\/www.emedicine.medscape.com\/article\/1911303-overview#a5. [Last accessed on 2015 Jun 28]."},{"key":"key-10.4103\/0378-6323.184199-44","first-page":"271","volume-title":"Current and emerging strategies in the management of venous thromboembolism: Benefit-risk assessment of dabigatran","author":"Fanola","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"key-10.4103\/0378-6323.184199-45","first-page":"1193","volume-title":"Acute phase treatment of VTE: Anticoagulation, including non-Vitamin K antagonist oral anticoagulants","author":"Hillis","year":"2015","journal-title":"Thromb Haemost"},{"key":"key-10.4103\/0378-6323.184199-46","first-page":"1406","volume-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","author":"Hokusai-VTE","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.184199-47","first-page":"2342","volume-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.184199-48","first-page":"764","volume-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","author":"Schulman","year":"2014","journal-title":"Circulation"},{"key":"key-10.4103\/0378-6323.184199-49","first-page":"395","volume-title":"Efficacy of dabigatran for dissolving deep vein thromboses in outpatients with a deteriorated general condition","author":"Fujino","year":"2015","journal-title":"Int Heart J"},{"key":"key-10.4103\/0378-6323.184199-50","first-page":"699","volume-title":"Apixaban for extended treatment of venous thromboembolism","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.184199-51","first-page":"799","volume-title":"Oral apixaban for the treatment of acute venous thromboembolism","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.184199-52","first-page":"7S","volume-title":"Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","author":"Guyatt","year":"2012","journal-title":"Chest"},{"key":"key-10.4103\/0378-6323.184199-53","first-page":"594","volume-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","author":"Lassen","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.184199-54","first-page":"807","volume-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"key-10.4103\/0378-6323.184199-55","first-page":"2487","volume-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","author":"Lassen","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.184199-56","first-page":"175","volume-title":"Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials","author":"Friedman","year":"2010","journal-title":"Thromb Res"},{"key":"key-10.4103\/0378-6323.184199-57","first-page":"1794","volume-title":"Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism","author":"Kearon","year":"2014","journal-title":"Blood"},{"key":"key-10.4103\/0378-6323.184199-58","first-page":"499","volume-title":"Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome","author":"Toubi","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"key-10.4103\/0378-6323.184199-59","first-page":"1730","volume-title":"Clinical significance of immunoglobulin A antiphospholipid antibodies: Possible association with skin manifestations and small vessel vasculitis","author":"Tajima","year":"1998","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0378-6323.184199-60","first-page":"19","volume-title":"Antiphospholipid syndrome: A review","author":"Dhir","year":"2014","journal-title":"J Mahatma Gandhi Inst Med Sci","ISSN":"https:\/\/id.crossref.org\/issn\/0971-9903","issn-type":"print"},{"key":"key-10.4103\/0378-6323.184199-61","doi-asserted-by":"crossref","unstructured":"Lateef A, Petri M. Clinical aspects of the antiphospholipid syndrome. In: Wallace DJ, Hahn BH, editors. Dubois' Lupus Erythematosus and Related Syndromes. 8th ed. Philadelphia: Elsevier Saunders; 2013. p. 518-25.","DOI":"10.1016\/B978-1-4377-1893-5.00042-X"},{"key":"key-10.4103\/0378-6323.184199-62","first-page":"951424","volume-title":"Treatment of Thrombotic antiphospholipid syndrome: The rationale of current management \u2013 An insight into future approaches","author":"Chighizola","year":"2015","journal-title":"J Immunol Res"},{"key":"key-10.4103\/0378-6323.184199-63","first-page":"2382","volume-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals","author":"Erkan","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.184199-64","first-page":"1560","volume-title":"Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: Prospective analysis of 404 individuals","author":"Gir\u00f3n-Gonz\u00e1lez","year":"2004","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0378-6323.184199-65","first-page":"997","volume-title":"Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis","author":"Ginsburg","year":"1992","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/0378-6323.184199-66","first-page":"37","volume-title":"Therapeutic strategies in antiphospholipid syndrome","author":"Cervera","year":"2010","journal-title":"Reumatol Clin"},{"key":"key-10.4103\/0378-6323.184199-67","first-page":"275","volume-title":"Low-dose aspirin vs.low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: A prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)","author":"Cuadrado","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"key-10.4103\/0378-6323.184199-68","first-page":"1133","volume-title":"Acomparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.184199-69","first-page":"848","volume-title":"Arandomized clinical trial of high-intensity warfarin vs.conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","author":"Finazzi","year":"2005","journal-title":"J Thromb Haemost"},{"key":"key-10.4103\/0378-6323.184199-70","first-page":"1487","volume-title":"A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies","author":"Ruiz-Irastorza","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.184199-71","first-page":"1498","volume-title":"Antiphospholipid syndrome","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet"},{"key":"key-10.4103\/0378-6323.184199-72","first-page":"358","volume-title":"Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative","author":"Coloma","year":"2013","journal-title":"Immunol Res"},{"key":"key-10.4103\/0378-6323.184199-73","first-page":"135","volume-title":"Anticoagulation treatment withdrawal in primary antiphospholipid syndrome when anticardiolipin antibodies become negative","author":"Criado-Garc\u00eda","year":"2008","journal-title":"Rev Clin Esp"},{"key":"key-10.4103\/0378-6323.184199-74","first-page":"6","volume-title":"Controversies in the antiphospholipid syndrome: Can we ever stop warfarin?","author":"Fonseca","year":"2008","journal-title":"J Autoimmune Dis"},{"key":"key-10.4103\/0378-6323.184199-75","first-page":"1652","volume-title":"Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome","author":"Vargas-Hitos","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0378-6323.184199-76","first-page":"S67","volume-title":"Long-term outpatient dalteparin (fragmin) therapy for arterial and venous thrombosis: Efficacy and safety \u2013 A preliminary report","author":"Bick","year":"1999","journal-title":"Clin Appl Thromb Hemost"},{"key":"key-10.4103\/0378-6323.184199-77","first-page":"135","volume-title":"Recurrent pregnancy loss with antiphospholipid antibody: A systematic review of therapeutic trials","author":"Empson","year":"2002","journal-title":"Obstet Gynecol"},{"key":"key-10.4103\/0378-6323.184199-78","first-page":"113","volume-title":"Antiphospholipid syndrome novel therapies","author":"Bittar","year":"2014","journal-title":"EMJ Rheumatol"},{"key":"key-10.4103\/0378-6323.184199-79","first-page":"680","volume-title":"Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome","author":"Noel","year":"2015","journal-title":"Autoimmun Rev"},{"key":"key-10.4103\/0378-6323.184199-80","first-page":"1035","volume-title":"The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases","author":"Son","year":"2015","journal-title":"Thromb Res"},{"key":"key-10.4103\/0378-6323.184199-81","first-page":"1087","volume-title":"Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: A prospective, randomized controlled phase II\/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE","author":"Cohen","year":"2015","journal-title":"Lupus"},{"key":"key-10.4103\/0378-6323.184199-82","unstructured":"Rivaroxaban in Thrombotic Antiphospholipid Syndrome (TRAPS). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02157272. [Last accessed on 2015 Jul 29]."},{"key":"key-10.4103\/0378-6323.184199-83","unstructured":"Rivaroxaban for Antiphospholipid Antibody Syndrome (RAPS). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02116036. [Last accessed on 2015 Jul 29]."},{"key":"key-10.4103\/0378-6323.184199-84","unstructured":"Apixaban for the Secondary Prevention of Thromboembolism among Patients with the Antiphospholipid Syndrome (ASTRO-APS). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02295475. [Last accessed on 2015 Jul 29]."},{"key":"key-10.4103\/0378-6323.184199-85","first-page":"499","volume-title":"Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: A pilot study","author":"Denton","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"key-10.4103\/0378-6323.184199-86","first-page":"531","volume-title":"Ischemic finger ulcer as a presenting symptom of systemic sclerosis","author":"Balbir-Gurman","year":"2005","journal-title":"Isr Med Assoc J"},{"key":"key-10.4103\/0378-6323.184199-87","first-page":"209","volume-title":"Sneddon syndrome with or without antiphospholipid antibodies.A comparative study in 46 patients","author":"Franc\u00e8s","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"key-10.4103\/0378-6323.184199-88","first-page":"215","volume-title":"Sneddon's syndrome: A comprehensive review of the literature","author":"Wu","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"key-10.4103\/0378-6323.184199-89","first-page":"10","volume-title":"Malignant atrophic papulosis (K\u00f6hlmeier-Degos disease) \u2013 A review","author":"Theodoridis","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"key-10.4103\/0378-6323.184199-90","doi-asserted-by":"crossref","unstructured":"Cox NH, Piette WW. Purpura and microvascular occlusion. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology. 8th ed. Oxford: Wiley-Blackwell; 2010. p. 49.1-49.51.","DOI":"10.1002\/9781444317633.ch49"},{"key":"key-10.4103\/0378-6323.184199-91","first-page":"1040","volume-title":"Low molecular weight heparin; a novel alternative therapeutic approach for lichen planus","author":"Stefanidou","year":"1999","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.184199-92","first-page":"604","volume-title":"Low-molecular-weight heparin (enoxaparin) in the treatment of lichen planus","author":"Ferahbas","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0378-6323.184199-93","first-page":"172","volume-title":"The effectiveness of treatment with enoxaparin in lichen planus","author":"U\u00e7mak","year":"2011","journal-title":"J Clin Exp Invest"},{"key":"key-10.4103\/0378-6323.184199-94","first-page":"76","volume-title":"Comparison of therapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs.oral prednisone in treatment of patients with lichen planus; A clinical trial","author":"Iraji","year":"2013","journal-title":"Adv Biomed Res","ISSN":"https:\/\/id.crossref.org\/issn\/2277-9175","issn-type":"print"},{"key":"key-10.4103\/0378-6323.184199-95","first-page":"93","volume-title":"Treatment of recalcitrant lichen planus with low molecular weight heparin (Enoxaparin): A case series study among Iraqi patients","author":"Ameen","year":"2011","journal-title":"Med J Babylon"},{"key":"key-10.4103\/0378-6323.184199-96","first-page":"37","volume-title":"Treatment of severe cutaneous ulcerative lichen planus with low molecular weight heparin in a patient with hepatitis C","author":"Neville","year":"2007","journal-title":"Cutis"},{"key":"key-10.4103\/0378-6323.184199-97","first-page":"236","volume-title":"A case of lichen planus significantly improved after topical heparinoid treatment","author":"Murao","year":"2013","journal-title":"Australas J Dermatol"},{"key":"key-10.4103\/0378-6323.184199-98","first-page":"349","volume-title":"Persistent generalized lichen nitidus successfully treated with enoxaparin sodium","author":"Cholongitas","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"key-10.4103\/0378-6323.184199-99","first-page":"281","volume-title":"Enoxaparin for the treatment of recurrent aphthous stomatitis: A pilot exploratory clinical trial","author":"Ghaffari","year":"2013","journal-title":"Minerva Stomatol"},{"key":"key-10.4103\/0378-6323.184199-100","first-page":"394","volume-title":"Recurrent aphthous stomatitis unresponsive to topical corticosteroids: A study of the comparative therapeutic effects of systemic prednisone and systemic sulodexide","author":"Femiano","year":"2003","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/0378-6323.184199-101","first-page":"605","volume-title":"Activation of blood coagulation in autoimmune skin disorders","author":"Cugno","year":"2009","journal-title":"Expert Rev Clin Immunol"},{"key":"key-10.4103\/0378-6323.184199-102","first-page":"384","volume-title":"Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: A pilot study","author":"Asero","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"key":"key-10.4103\/0378-6323.184199-103","first-page":"204","volume-title":"Dermatitis herpetiformis effectively treated with heparin, tetracycline and nicotinamide","author":"Shah","year":"2000","journal-title":"Clin Exp Dermatol"},{"key":"key-10.4103\/0378-6323.184199-104","first-page":"185","volume-title":"A rare case of dermatitis herpetiformis requiring parenteral heparin for long-term control","author":"Tan","year":"1996","journal-title":"Dermatology"},{"key":"key-10.4103\/0378-6323.184199-105","first-page":"90","volume-title":"Full blown case of lipoid proteinosis","author":"Kachewar","year":"2011","journal-title":"MJAFI"},{"key":"key-10.4103\/0378-6323.184199-106","first-page":"7","volume-title":"Uremic pruritus: Still itching","author":"A\u015f\u0131c\u0131o\u011flu","year":"2011","journal-title":"Turk Neph Dial Transpl"},{"key":"key-10.4103\/0378-6323.184199-107","doi-asserted-by":"crossref","unstructured":"James WD, Berger TG, Elston DM, editors. Contact dermatitis and drug eruptions. In: Andrews' Diseases of the Skin Clinical Dermatology. 11th ed. Philadelphia: Elsevier Saunders; 2011. p. 88-137.","DOI":"10.1016\/B978-1-4377-0314-6.00006-1"},{"key":"key-10.4103\/0378-6323.184199-108","first-page":"96","volume-title":"Warfarin-induced skin necrosis","author":"Kakagia","year":"2014","journal-title":"Ann Dermatol"},{"key":"key-10.4103\/0378-6323.184199-109","first-page":"47","volume-title":"Late onset warfarin induced skin necrosis in human immunodeficiency virus infected patient with pulmonary tuberculosis","author":"Choudhary","year":"2013","journal-title":"Indian J Sex Transm Dis","ISSN":"https:\/\/id.crossref.org\/issn\/0253-7184","issn-type":"print"},{"key":"key-10.4103\/0378-6323.184199-110","unstructured":"Xin C, Hu D, Li M. Late onset warfarin-induced skin necrosis, a case report. G Ital Dermatol Venereol 2014; [Epub ahead of print]."},{"key":"key-10.4103\/0378-6323.184199-111","unstructured":"McGevna LF, Raugi GJ, Raza SR. Cutaneous Manifestation of Cholesterol Embolism Clinical Presentation. Available from: http:\/\/www.emedicine.medscape.com\/article\/1096593-clinical. [Last accessed on 2015 Aug 04]."},{"key":"key-10.4103\/0378-6323.184199-112","unstructured":"McGevna LF, Raugi GJ, Raza SR. Cutaneous Manifestation of Cholesterol Embolism Treatment and Management. Available from: http:\/\/www.emedicine.medscape.com\/article\/1096593-treatment. [Last accessed on 2015 Aug 04]."},{"key":"key-10.4103\/0378-6323.184199-113","unstructured":"Piette WW. Cutaneous manifestations of microvascular occlusion syndromes. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. London: Elsevier; 2008. p. 369-84."},{"key":"key-10.4103\/0378-6323.184199-114","first-page":"63","volume-title":"Heparin-induced thrombocytopenia","author":"Krzych","year":"2015","journal-title":"Anaesthesiol Intensive Ther"},{"key":"key-10.4103\/0378-6323.184199-115","first-page":"e2015029","volume-title":"Is the incidence trend of heparin-induced thrombocytopenia decreased by the increased use of low-molecular-weight-heparin?","author":"Al-Eidan","year":"2015","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"key-10.4103\/0378-6323.184199-116","first-page":"1838","volume-title":"Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia","author":"Lewis","year":"2001","journal-title":"Circulation"},{"key":"key-10.4103\/0378-6323.184199-117","first-page":"1044","volume-title":"Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia","author":"Joseph","year":"2014","journal-title":"J Thromb Haemost"},{"key":"key-10.4103\/0378-6323.184199-118","first-page":"340S","volume-title":"Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","author":"Warkentin","year":"2008","journal-title":"Chest"},{"key":"key-10.4103\/0378-6323.184199-119","doi-asserted-by":"crossref","unstructured":"Breathnach SM. Drug reactions. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology. 8th ed. Oxford: Wiley-Blackwell; 2010. p. 75.1-75.117.","DOI":"10.1002\/9781444317633.ch75"},{"key":"key-10.4103\/0378-6323.184199-120","first-page":"66","volume-title":"Lovenox induced tissue necrosis, a case report and literature review","author":"Issa","year":"2015","journal-title":"J Am Coll Clin Wound Spec"},{"key":"key-10.4103\/0378-6323.184199-121","first-page":"1068","volume-title":"Subcutis calcinosis caused by injection of calcium-containing heparin in a chronic kidney injury patient","author":"Fatma","year":"2014","journal-title":"Saudi J Kidney Dis Transpl","ISSN":"https:\/\/id.crossref.org\/issn\/1319-2442","issn-type":"print"},{"key":"key-10.4103\/0378-6323.184199-122","first-page":"4","volume-title":"An unusual adverse effect of nadroparin injections: Calcinosis cutis","author":"Nuno-Gonzalez","year":"2011","journal-title":"Dermatol Online J"},{"key":"key-10.4103\/0378-6323.184199-123","first-page":"1585","volume-title":"Delayed cutaneous hypersensitivity reactions to hirudin","author":"Smith","year":"2001","journal-title":"Arch Pathol Lab Med"},{"key":"key-10.4103\/0378-6323.184199-124","first-page":"47","volume-title":"Telogen effluvium revisited","author":"Rebora","year":"2014","journal-title":"G Ital Dermatol Venereol"},{"key":"key-10.4103\/0378-6323.184199-125","first-page":"513","volume-title":"Enoxaparin-induced alopecia in patients with cerebral venous thrombosis","author":"Wang","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"key-10.4103\/0378-6323.184199-126","first-page":"256","volume-title":"Aplasia cutis congenita and low molecular weight heparin","author":"Sharif","year":"2005","journal-title":"BJOG"},{"key":"key-10.4103\/0378-6323.184199-127","first-page":"524","volume-title":"A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons","author":"Brown","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.184199-128","first-page":"535","volume-title":"Novel oral anticoagulants: What dermatologists need to know","author":"Plovanich","year":"2015","journal-title":"J Am Acad Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology, and Leprology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T10:45:37Z","timestamp":1611917137000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijdvl.com\/anticoagulants-in-dermatology\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":128,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"alternative-id":["184199"],"URL":"https:\/\/doi.org\/10.4103\/0378-6323.184199","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}